Sun Pharmaceutical’s (Sun) Q1FY24 performance was driven by better sales of generics in the US, while specialty growth took a back seat. US generics’ business ex-Taro rose 10% QoQ. Impact of lower sales of Levulan in Q1 was largely offset by higher sales of gRevlimid (estimated at USD 35-40mn) and helped Sun report an in-line result.